West Pharmaceutical Services - WST Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" WST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WST, but not buy additional shares or sell existing shares.
View WST analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month price objectives for West Pharmaceutical Services' shares. Their WST share price forecasts range from $250.00 to $375.00. On average, they expect the company's share price to reach $291.25 in the next twelve months. This suggests that the stock has a possible downside of 15.9%.
View analysts price targets for WST or view top-rated stocks among Wall Street analysts.

West Pharmaceutical Services' stock was trading at $235.35 at the beginning of the year. Since then, WST shares have increased by 47.2% and is now trading at $346.47.
View the best growth stocks for 2023 here.

West Pharmaceutical Services saw a increase in short interest in February. As of February 15th, there was short interest totaling 1,670,000 shares, an increase of 24.6% from the January 31st total of 1,340,000 shares. Based on an average daily trading volume, of 629,800 shares, the days-to-cover ratio is currently 2.7 days. Approximately 2.3% of the company's stock are short sold.
View West Pharmaceutical Services' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our WST earnings forecast.

West Pharmaceutical Services, Inc. (NYSE:WST) issued its quarterly earnings data on Thursday, February, 16th. The medical instruments supplier reported $1.77 earnings per share for the quarter, beating analysts' consensus estimates of $1.39 by $0.38. The medical instruments supplier had revenue of $708.70 million for the quarter, compared to analysts' expectations of $657.16 million. West Pharmaceutical Services had a net margin of 20.30% and a trailing twelve-month return on equity of 26.24%. The firm's revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.04 EPS.
Read the conference call transcript.

West Pharmaceutical Services announced a quarterly dividend on Friday, March 3rd. Stockholders of record on Wednesday, April 26th will be given a dividend of $0.19 per share on Wednesday, May 3rd. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date is Tuesday, April 25th.
Read our dividend analysis for WST.

ETFs with the largest weight of West Pharmaceutical Services (NYSE:WST) stock in their portfolio include Invesco Dynamic Market ETF (PWC), Nuveen ESG Mid-Cap Growth ETF (NUMG), BlackRock Future Health ETF (BMED), Invesco S&P 500 Equal Weight Health Care ETF (RYH), First Trust Indxx Medical Devices ETF (MDEV), Invesco S&P 500 GARP ETF (SPGP), ProShares S&P 500 Aristocrats ETF (NOBL) and Siren DIVCON Leaders Dividend ETF (LEAD).

West Pharmaceutical Services (NYSE:WST) pays an annual dividend of $0.76 per share and currently has a dividend yield of 0.22%. The company has been increasing its dividend for 30 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.84%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, WST will have a dividend payout ratio of 9.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for WST.

West Pharmaceutical Services issued an update on its FY 2023 earnings guidance on Monday, February, 20th. The company provided earnings per share guidance of $7.25-$7.40 for the period, compared to the consensus estimate of $7.27. The company issued revenue guidance of $2.94 billion-$2.96 billion, compared to the consensus revenue estimate of $2.87 billion.

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $346.47.

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $25.73 billion and generates $2.89 billion in revenue each year. The medical instruments supplier earns $585.90 million in net income (profit) each year or $7.72 on an earnings per share basis.

The company employs 13,550 workers across the globe.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for the company is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at quintin.lai@westpharma.com, or via fax at 800-345-9800.